Background: The high prevalence and chronic nature of psoriasis leads to high costs in relation to the treatment and control of the disease. A number of clinical trials have shown that a combination therapy of calcipotriol cream (Daivonex®/Dovonex®, Leo Pharmaceutical Products) and ultraviolet B phototherapy (UVB) decreases the total number of UVB exposures required compared to UVB treatment alone. From a societal point of view, the addition of calcipotriol to UVB therapy could achieve cost savings due to the fewer UVB treatments needed and the reduced travelling and time off work for patients. Fewer UVB exposures may also have other beneficial effects, i.e., shortened waiting lists and less risk to patients of developing cancer or photoaging of the skin. Objective: To compare the cost-effectiveness of treating psoriatic patients in the Netherlands with calcipotriol cream used daily combined with twice weekly UVB treatments to emollient used daily combined with UVB given 3 times weekly. Methods: Based on the clinical results from a Canadian trial, a decision-analytical model was constructed to simulate treatment outcomes and estimate the costs of managing psoriatic patients in the Netherlands over a period of 20 weeks from initiation of therapy. Unit costs and details of standard treatment protocols were collected from Dutch dermatology centres in hospitals and the community for use in the model. Other therapies, such as topical corticosteroids, tar or dithranol were not investigated in this analysis. Results: The total cost of managing psoriatic patients in the Netherlands over a 20-week period is estimated as EUR 1,175.90 for those treated with calcipotriol and UVB and EUR 1,212.14 for patients treated with emollient and UVB. Thus, the former treatment, adding calcipotriol to UVB phototherapy, provides a minor cost saving of EUR 36.24 (3%) compared to the cost of UVB treatment alone. Sensitivity analyses demonstrated that these results are sensitive to changes in the cost of UVB treatment. Conclusion: Calcipotriol treatment combined with UVB phototherapy is a cost-neutral alternative to UVB phototherapy used with an emollient. The patients achieve treatment success in the same time on both treatments but the former, with calcipotriol, requires less exposure to UVB radiation. The additional drug costs from using calcipotriol are offset by savings from the fewer UVB sessions required. Essential beneficial effects for patients are less inconvenience, less risk of developing photoaging of the skin and less exposure to potentially carcinogenic radiations.

Keywords:
Psoriasis, Calcipotriol, Daivonex®, Dovonex®, Cost, Pharmacoeconomic evaluation, Markov model, Ultraviolet B
1.
Touw CR, Koopmanschap MA: Kosten van Psoriasis in Nederland. Ned Tijdschr Dermatol Venerol 1998;8:215–219.
2.
Molin L and the Calcipotriol-UVB Study Group: Topical calcipotriol combined with phototherapy for psoriasis. Dermatology 1999;198:375–381.
3.
Ramsay C: Calcipotriol cream and UVB phototherapy in psoriasis. J Invest Dermatol 1998;110:686.
4.
Stern RS: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation and ultraviolet B radiation. N Engl J Med 1990;332:1093–1097.
5.
Pasker-de Jong PC, Wielink G, van der Valk PGM, van der Wilt GJ: Treatment with UV-B for psoriasis and nonmelanoma skin cancer. Arch Dermatol 1999;135:834–840.
6.
Lambert JRMG: Economic analyses of the treatment of psoriasis. Eur J Dermatol 1996;6:543–546.
7.
Sander HM, Morris LF, Philips CM, Harrison PE, Menter A: The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422–425.
8.
Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR: The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564–569.
9.
Chen S, Shaheen A, Garber A: Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis: A pilot study. Arch Dermatol 1998;134:1602–1608.
10.
Marchetti A, LaPensée K, An P: A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: A US study. Clin Ther 1998;20:851–869.
11.
Oh PI, Gupta AK, Einarson TR, Maerov P, Shear NH: Calcipotriol in the treatment of psoriasis of limited severity: Pharmacoeconomic evaluation. J Cutan Med Sur 1997;2:7–15.
12.
Ramsay C, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M and other members of the Canadian Calcipotriol and UVB Study Group: Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatic combination treatment. Dermatology, 2000;200:17–24.
13.
Van de Kerkhof PCM, de Hoop D, de Korte J, Cobelens SA, Kuipers MV: Patient compliance in the treatment of psoriasis. Dermatology 2000, in press.
14.
Sonnenberg FA, Beck JR: Markov models in medical decision making. Med Decis Making 1993;13:322–338.
15.
Rutten FFH, Ineveld BM, Ommen R, Hout BA van, Huijsman R: Kostenberekening bij Gezondheidszorgonderzoek. Rapport opgesteld in opdracht van de Stuurgroep Toekomstscenario’s Gezondheidszorg. Utrecht, 1993.
16.
CBS: Sociaal-economische maandstatistiek, 1996/11.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.